Showing results (231-240 of 340) with videos related to
Sort By:
Pageof 34
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 12, 2013
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)Hiddo J Lambers Heerspink, Misghina Weldegiorgis, Lesley A Inker, et al.Journal of Hypertension|August 4, 2015
Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetesMichelle J Pena, Joachim Jankowski, Georg Heinze, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 20, 2015
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)Elise Schutte, Hiddo J Lambers Heerspink, Helen L Lutgers, et al.Kidney International|March 13, 2003
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Barry M Brenner, Dick de Zeeuw, et al.Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.The American Journal of Cardiology|June 30, 2007
Effect of first myocardial ischemic event on renal functionWouter B A Eijkelkamp, Pieter A de Graeff, Dirk J van Veldhuisen, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.Journal of Cardiac Failure|October 14, 2014
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methylMelanie P Chin, Danielle Wrolstad, George L Bakris, et al.Diabetologia|March 15, 2019
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS ProgramDavid R Matthews, Qiang Li, Vlado Perkovic, et al.Diabetes Care|December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.Pageof 34